The project of taxol derivative, a class I and type II new antidiabetic drug of Haixi United Pharmaceutical Co., Ltd. was officially launched in Mingxi

Fujian Haixi United Pharmaceutical Co., Ltd and China University of Pharmaceutical Sciences jointly implemented a class I new drug taxol derivative (type II new anti diabetes drug) project, which was officially implemented in Mingxi economic development zone The new type Ⅱ antidiabetic drug can significantly reduce hyperglycemia, inhibit glycogen decomposition and glucose absorption, effectively control postprandial blood glucose without hypoglycemic reaction, with small side effects and strong safety, which is conducive to long-term medication The total investment of the project is 200 million yuan, with a total construction area of 32800 square meters It is planned to build multi-functional apt production workshop, GMP preparation workshop, experimental complex building and related supporting facilities After the completion of the project, the annual output value of the new type II antidiabetic drugs is 250 million yuan and the profit and tax are 40 million yuan News extension: accelerate the construction of Haixi United Pharmaceutical Project Fujian Mingxi Haixi United Pharmaceutical Co., Ltd is located in the economic development zone of Mingxi County It is a private scientific and technological enterprise specializing in new technologies and products such as fluorine-containing inhaled anesthetics, photodynamic therapy drugs and new nano slow-release and control The total investment is 150 million yuan The first phase project is planned to invest 70 million yuan Up to now, 60 million yuan has been invested The company has the first comprehensive fluorine-containing inhalational anesthetic raw material drug and its preparation production line in China The desflurane developed by the company belongs to three categories of drugs, which is currently created in China and is the company's superior product At present, five products, such as desflurane, sevoflurane, isoflurane, trifluoroethyldifluoromethane, hexafluoroisopropyl chloromethyl ether, have been put into trial production, and the registration and application of four drug numbers, such as desflurane and sevoflurane, are being accelerated In recent years, Haixi United Pharmaceutical Co., Ltd has made great efforts to promote the construction of advanced production facilities and related supporting projects, such as the production line of various inhaled anesthetics, the production line of inhaled anesthetics raw materials and preparations, the production line of photodynamic drugs chemical synthesis, the production line of raw materials, the production line of photodynamic drugs, and the production line of oral solid preparations The company has formed strong partners with Delger group of Germany, cristalia of Brazil, Hengrui pharmaceutical of Jiangsu Province, Nanfang pharmaceutical of Fujian Province, hiSoft of Sanming City, etc., relying on the Shanghai R & D center and Mingxi R & D platform, built and produced GMP compliant API workshops, developed various chemical synthetic drugs, developed and approved more than two export-oriented solid preparation projects every year, and is the first in China It will promote the development and production of new drugs such as photodynamic drugs, new oral solid preparations and new anti-tumor drugs Zhu Jihong, general manager of the company, said that after the completion of the project, 1000 tons of inhalational anesthetics and intermediates can be produced annually, with an annual sales volume of 300 million yuan and a profit tax of 20 million yuan.